Cargando…
Early neutropenia on day 8 treated with adjuvant Docetaxel-based chemotherapy in early breast cancer patients: Putative mechanisms within the neutrophil pool system
Most chemotherapy regimens cause neutropenic nadirs between days 10 and 14, and administration of granulocyte colony-stimulating factor (G-CSF) support relies on this timing. In docetaxel (DOC)-based chemotherapy, the frequency of febrile neutropenia (FN) and the G-CSF dose administered varied great...
Autor principal: | Furuya, Yoshihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472781/ https://www.ncbi.nlm.nih.gov/pubmed/30998754 http://dx.doi.org/10.1371/journal.pone.0215576 |
Ejemplares similares
-
Changes in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle
por: Yoshimura, Keiko, et al.
Publicado: (2014) -
Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer
por: Cameron, D A, et al.
Publicado: (2003) -
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
por: Ellis, Paul, et al.
Publicado: (2009) -
Adjuvant Chemotherapy for Breast Cancer in a Patient with Primary Autoimmune Neutropenia
por: Trus, Michael, et al.
Publicado: (2013) -
Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
por: Ray-Coquard, I, et al.
Publicado: (2003)